NCT00803556 - Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Solid TumorBreast Cancer

Interventions

DRUG

Alvespimycin

Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT

DRUG

Trastuzumab

Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT

DRUG

Paclitaxel

Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT

Trial Locations (2)

Memorial Sloan Kettering Cancer Center, New York

Indiana University Melvin & Bren Simon Cancer Center, Indianapolis